Paladin Labs Inc.: Health Canada Requires Additional Information For GlucaGen'R' Approval

Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that its partner, Novo Nordisk Canada Inc., has been advised by the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada, that its application for GlucaGen® (recombinant glucagon for injection) has received a Notice of Deficiency. It is expected that Health Canada's issues will be responded to within the prescribed 90-day window.